Synageva Biopharma Corporation

Avigenics, Inc.

University of Georgia Research Foundation, Inc.

Alexion Pharmaceuticals, Inc.

University of Iowa Research Foundation

Avigentics, Inc.

Synageva Biopharm Corp.

Alex J Harvey

Jeffrey C Rapp

Robert D Ivarie

Julie A Morris

Guodong Liu

Markley C Leavitt

Youliang Wang

Anthony Quinn

Leandro Christmann

Zhinan Xia

Dawn M Eberhardt

Stephen H Parker

The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

Lysosomal storage disease enzymes

A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.

Method of using a transgenic chicken to produce exogenous proteins in its eggs

The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.

NPP1 fusion proteins

The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.

Avian derived antibodies

The invention includes isolating pharmaceutical proteins from avian hard shell eggs containing pharmaceutical proteins wherein the pharmaceutical proteins are exogenous to the egg.

Method of making protein in an egg of a transgenic chicken

This invention provides for proteins which are expressed in the avian oviduct, packaged into eggs laid by the avian, then isolated.

Production of exogenous proteins in egg whites of transgenic chickens

This invention provides vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of a bird and for expressing said exogenous sequences to alter the phenotype of the bird or to produce desired proteins. In particular, transgenic chickens are produced which express exogenous sequences in their oviducts. Eggs which contain exogenous proteins are also produced.

Transgenic chickens producing exogenous protein in eggs

Transgenic avians which produce proteins in their oviduct tissue having modified oligosaccharide structures and methods of making such avians are disclosed herein. The invention also includes the modified proteins produced in the transgenic birds.

Method of producing sialytransferase-modified proteins

Nucleic acid construct having an ovalbumin promotor

The invention provides for antibodies produced in transgenic birds as chickens.

Antibodies produced in a transgenic avian egg white

The invention encompasses among other things fusion proteins including Fc fusion proteins such as CTLA4-Fc having avian N-linked glycosylation patterns obtained from egg white of eggs laid by transgenic avians.

Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken

This invention provides for proteins which are expressed in the avian oviduct, packaged into eggs laid by the avian and removed from the eggs.

Growing community of inventors

Athens, GA, United States of America

Alex J Harvey